Related Experiment Videos
The concept of cardioreparation: Part 2. Medical implications of cardioreparation
J G Cleland1, N G Dewhurst, R L Murphy
1Clinical Research Initiative in Heart Failure, University of Glasgow, UK.
Insights
Angiotensin converting enzyme (ACE) inhibitors may reverse cardiac remodeling, improving outcomes for heart failure and heart attack patients. This cardioreparation concept offers potential for better cardiac function and prognosis.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Left ventricular hypertrophy (LVH) from hypertension, myocardial infarction, and heart failure leads to pathological cardiac remodeling.
- Cardioreparation, the reversal of cardiac remodeling, offers a potential therapeutic strategy to restore normal cardiac structure and function.
- Understanding cardioreparation could improve prognoses for patients with cardiovascular diseases.
Purpose of the Study:
- To explore the medical implications of cardioreparation.
- To investigate the role of ACE inhibitors in cardioreparation.
- To assess the impact of cardioreparation on cardiac structure and function.
Main Methods:
- Review of clinical trials involving ACE inhibitors and other drugs.
- Analysis of drug effects in patients with hypertension, myocardial infarction, and congestive heart failure.
- Evaluation of observed clinical outcomes in relation to cardioreparation.
Main Results:
- ACE inhibitors demonstrated regression of LVH in hypertensive patients.
- ACE inhibitors reduced mortality in acute myocardial infarction.
- ACE inhibitors decreased morbidity and mortality in heart failure and post-myocardial infarction left ventricular dysfunction.
Conclusions:
- ACE inhibitors significantly reduce morbidity and mortality in myocardial infarction and congestive heart failure patients.
- Clinical evidence suggests that the benefits of ACE inhibitors may stem from cardioreparation.
- Cardioreparation represents a promising therapeutic avenue for cardiovascular disease management.
Purpose:
Left ventricular hypertrophy (LVH) caused by systemic hypertension, myocardial infarction and congestive heart failure is associated with pathological changes in the structure of the heart, collectively described as remodelling (see part 1 of this review). The reversal of remodelling, termed cardioreparation, might restore cardiac structure and function towards normal, thereby improving the prognosis of these conditions. We aimed to explore the medical implications of this concept.
Data Extraction:
Clinical trials of angiotensin converting enzyme (ACE) inhibitors and other drugs in patients with hypertension, myocardial infarction and congestive heart failure were reviewed. The results showed that ACE inhibitors induce regression of LVH in hypertensive patients, reduce mortality in acute myocardial infarction, and reduce morbidity and mortality in patients with congestive heart failure or left ventricular dysfunction subsequent to myocardial infarction. These observations are consistent with cardioreparation by ACE inhibitors.
Conclusions:
ACE inhibitors reduce morbidity and mortality in patients with myocardial infarction or congestive heart failure. Theoretical considerations and some clinical observations suggest that these benefits might result from cardioreparation.